MAIA BIOTECHNOLOGY INC (MAIA) Stock Price, Forecast & Analysis
NYSEARCA:MAIA • US5526411021
MAIA Key Statistics, Chart & Performance
The current stock price of MAIA is 1.94 USD. In the past month the price increased by 14.19%. In the past year, price decreased by -5.35%.
MAIA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MAIA. When comparing the yearly performance of all stocks, MAIA is one of the better performing stocks in the market, outperforming 87.05% of all stocks.
MAIA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MAIA. MAIA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MAIA Financial Highlights
Over the last trailing twelve months MAIA reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 46.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.41% | ||
| ROE | -417.16% | ||
| Debt/Equity | 0 |
MAIA Forecast & Estimates
7 analysts have analysed MAIA and the average price target is 10.48 USD. This implies a price increase of 439.97% is expected in the next year compared to the current price of 1.94.
MAIA Ownership
MAIA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.63 | 390.397B | ||
| AMGN | AMGEN INC | 16.36 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.13 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.64 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.04 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.64 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.81 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.2 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MAIA
Company Profile
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
Company Info
MAIA BIOTECHNOLOGY INC
444 West Lake Street, Suite 1700, Suite 1700
Chicago ILLINOIS US
Employees: 13
Phone: 13124168592
MAIA BIOTECHNOLOGY INC / MAIA FAQ
What does MAIA do?
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
What is the current price of MAIA stock?
The current stock price of MAIA is 1.94 USD. The price increased by 9.6% in the last trading session.
Does MAIA stock pay dividends?
MAIA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MAIA stock?
MAIA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is MAIA BIOTECHNOLOGY INC (MAIA) stock traded?
MAIA stock is listed on the NYSE Arca exchange.
Would investing in MAIA BIOTECHNOLOGY INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MAIA.